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R-PEP-27, a Potent Renin Inhibitor, 
Decreases Plasma Angiotensin II and Blood 
Pressure in Normal Volunteers 
Randall M. Zusman, Kwan Y. Hui, Jürg Nussberger, Donna M. Christensen, Joy Higgins, 
William D. Carlson, David Schoenfeld, and Edgar Haber 
The hemodynamic and humoral effects of the spe­
cific human renin inhibitor R-PEP-27 were studied 
in six normal human subjects on low and high so­
dium intake diets. An intravenous infusion of 
R-PEP-27 (0.5 to 16 μg/min/kg body wt) reduced 
blood pressure in a dose-dependent fashion; the 
mean arterial blood pressure at the end of the infu­
sion fell from 128 ± 4/83 ± 4 to 119 ± 3/71 ± 3 mm 
Hg (mean ± SEM) (Ρ < .01) during the low so­
dium intake diet. R-PEP-27 had no effect on blood 
pressure during the high sodium intake diet. 
R-PEP-27 significantly reduced plasma angiotensin 
II and aldosterone concentrations. The temporal 
response to R-PEP-27 suggests that it is a short­
lived although highly potent competitive inhibitor 
of renin; this peptide is a valuable and specific 
physiologic probe of the renin-angiotensin system. 
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The renin-angiotensin-aldosterone system was first described as a regulator of systemic vascular resistance, intravascular volume, and blood pressure and as a circulating hor­
monal system mediated by the vasoconstricting oc-
tapeptide angiotensin II and the adrenal steroid aldo-
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sterone. Because of the importance of the renin-
angiotensin system in sustaining the blood pressure 
of hypertensive humans and the pathophysiologic 
role of perturbations of this system in congestive 
heart failure, attention has been focused on the de­
velopment of inhibitors of the renin-angiotensin cas­
cade. 1 2 The first inhibitor of this system was sarala-
sin, an angiotensin II receptor antagonist. 3 More 
recently, non-peptide angiotensin II receptor antago­
nists have been developed; these substances, primar­
ily imidazole derivatives, are effective in antagoniz­
ing angiotensin II-mediated vasoconstriction. Unlike 
saralasin, however, they have no agonistic activity; in 
addition, they can be administered orally rather than 
parenterally. 4 ' 5 
Inhibition of the formation of angiotensin II 
through the use of angiotensin-converting enzyme 
(ACE) inhibitors has become clinically important in 
the treatment of patients with hypertension, conges­
tive heart failure, or both. However, the specificity of 
their antihypertensive effect with regard to the renin-
angiotensin system has been questioned because of 
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the efficacy of Captopril, in particular, under condi­
tions of renin suppression. The physiologic and ther­
apeutic benefits of converting enzyme inhibition thus 
might result not only from inhibition of the renin-
angiotensin cascade, but also from non-renin-
mediated mechanisms of vasodilation. 6 
An alternative to angiotensin II receptor blockade 
or converting enzyme inhibition is interruption of the 
proximate step in the renin-angiotensin-aldosterone 
cascade, the inhibition of renin itself. The conversion 
of angiotensinogen to angiotensin I is the rate-
limiting step in the generation of the biologic effector 
angiotensin II. Since the original description of a com­
petitive renin-inhibitory peptide, 7 a number of com­
pounds have been described that inhibit renin's in­
teraction with its sole substrate, angiotensinogen. 8 
These agents have the potential advantage of inhib­
iting the generation of angiotensin I within the intra­
vascular space; in addition, if they penetrate into ex­
tra vascular sites of renin activity, they could decrease 
intracellular angiotensin II generation. Intracellularly, 
the physiologic importance of the angiotensin-
converting enzyme as a promoter of the formation of 
angiotensin II from angiotensin I has been ques­
tioned. Thus, the effects of a renin inhibitor might 
exceed those of ACE inhibition. The use of a compet­
itive renin inhibitor as a physiologic probe might al­
low isolation of the effects of renin inhibition from the 
potential non-renin-dependent mechanisms of action 
of the converting enzyme inhibitors or angiotensin II 
receptor antagonists. 
The renin inhibitory peptide R-PEP-27 (Pro-His-
Pro-Phe-His-Statine-Ile-Phe-NH2) is a potent sub­
strate analog; its I C 5 0 in vitro against human plasma 
renin at pH 7.4 is 9.5 nmol/L when renin activity is 
measured by the antibody-trapping technique 9 as 
adapted from Poulsen and Jorgensen, 1 0 which indi­
cates greater potency than that of other clinically 
tested renin inhibitors such as CGP 38560A or 
enalkiren (A-64662) and equivalent potency to the 
orally active renin inhibitor RO 42-5892. The infusion 
of this renin inhibitory peptide into sodium-depleted 
Macaca fascicularis monkeys produces a dose-
dependent reduction in blood pressure and plasma 
renin activity in association with a fall in plasma an­
giotensin II concentrations. 1 1 The purpose of the 
present investigation was to determine the blood 
pressure, heart rate, and humoral effects of a graded 
infusion of the renin inhibitory peptide R-PEP-27 in 
human subjects during both dietary sodium restric­
tion and sodium repletion. 
METHODS 
Six subjects (five men, one woman, age range 31 to 61 
years) were studied. Each subject gave written in­
formed consent before participation. The clinical pro­
tocol was approved by the Subcommittee on Human 
Studies of the Committee on Research of the Massa­
chusetts General Hospital. 
Each subject was admitted to the General Clinical 
Research Center of the Massachusetts General Hos­
pital and was given a metabolic diet containing either 
200 mEq or less than 10 mEq of sodium; the diet con­
tained 100 mEq of potassium. All subjects had unlim­
ited access to distilled water. On the sixth day of each 
diet, each subject received R-PEP-27. Each subject in­
gested the high and the low salt intake diet; the order 
of the diets was randomized among the six subjects. 
Urine was collected daily for the measurement of 24-h 
sodium, potassium, and creatinine excretion. 
R-PEP-27 Infusion Protocol R-PEP-27 was synthe­
sized and purified as previously descr ibed. 1 1 , 1 2 The 
renin-inhibitory peptide, dissolved in a solution of 
5% dextrose and water (final concentration, approxi­
mately 0.5 mg/mL), was infused using a variable-rate 
Harvard infusion pump at 0.5, 1, 2, 4, 8, and 16 μg/ 
min/kg body wt. Each dose was infused consecutive­
ly for 10 min, for a total of 60 min. Blood pressure was 
measured by sphygmomanometer every 2 min, be­
ginning 30 min before the onset of the infusion until 
60 min after completion of the infusion in the supine 
position. For the subsequent hour, blood pressure 
was determined every 15 min for an additional 60 min 
in both the supine and upright positions. 
During the 9th minute of each 10-min interval, the 
subjects were placed in the upright position at an 
angle of 70° using a mechanized tilt table. Blood pres­
sure was determined in the upright position during 
the 10th minute before initiation of the next infusion 
period. 
Blood samples for the measurement of angiotensin 
II and aldosterone concentrations were obtained ev­
ery 10 min (immediately before the patient assumed 
the upright position) beginning 20 min before the be­
ginning of the infusion until 1 h after completion of 
the infusion. Blood samples were obtained every 30 
min dμring the final hour. A total of 510 mL of blood 
was removed during the two dietary experimental 
periods. The blood was collected into prechilled 
tubes, centrifuged in a refrigerated centrifuge, and 
immediately frozen for storage before assay. 
Blood volumes removed for biochemical determi­
nations were replaced by intravenous injection of an 
equal volume of normal saline solution. Continuous 
electrocardiographic monitoring was maintained 
throughout administration of the renin-inhibitory 
peptide and converting enzyme inhibitor. Aldoste­
rone concentration (Aldosterone TKAL Radioimmu­
noassay Kit, Diagnostic Products, Los Angeles, 
C A ) , 1 3 , 1 4 and angiotensin II concentrations 1 5 were de­
termined as previously described. 
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Briefly, angiotensins were extracted from plasma 
by reversible adsorption to phenylsilylsilica, sepa­
rated by reversed-phase HPLC, and eight fractions of 
105 μι mobile phase potentially containing angioten-
sin-(l-8)octapeptide were directly collected into 1-mL 
albumin buffer for radioimmunoassay. Using these 
procedures, overall recovery of angiotensin II added 
to plasma is consistently above 85%. If none of the 
eight HPLC fractions contained measurable angioten­
sin II, one fraction was considered to contain the pep­
tide at the detection limit of 0.16 fmol; thus the min­
imal angiotensin II concentration that could be mea­
sured in 2 mL of plasma was 0.1 fmol/mL. 
Statistical Analysis Baseline values were deter­
mined by averaging blood pressure measurements or 
laboratory results obtained during the 30-min period 
preceding administration of the renin inhibitor. Mea­
surements at the end of each renin-inhibitor infusion 
dose and during subsequent observation were deter­
mined by averaging values over the final 4 min of 
each 10-min interval. 
All data are presented as the mean ± standard er­
ror of the mean. An analysis of variance (ANOVA) 
followed by t tests was used to test whether the dif­
ference between baseline values and values obtained 
during infusion of the peptide were significant. 
RESULTS 
Metabolic Homeostasis Each subject achieved met­
abolic balance on or before the fifth day of each so­
dium intake diet. Neither urinary sodium excretion 
(less than 5 mEq and 183 ± 8 mEq/24 h), potassium 
excretion (77 ± 7 and 84 ± 5 mEq/24 h), nor creatinine 
excretion (1448 ± 127 and 1468 ± 115 mg/24 h) during 
low and high salt intake diets, respectively, were 
affected by treatment with the renin inhibitor 
R-PEP-27. 
Blood Pressure The renin inhibitor induced a dose-
dependent and significant reduction in systolic, dia­
stolic, and mean arterial pressure (calculated as the 
diastolic blood pressure plus one-third the pulse 
pressure) measured in the supine position during in­
gestion of the low-sodium diet; the reductions in sys­
tolic, diastolic, and mean blood pressure at the end of 
the peptide infusion were 8.8 ± 2.2, 11.5 ± 1.1, and 
10.4 ± 1 . 9 mm Hg (P < .01 for each value), respec­
tively (Figure 1, Table 1). 
The blood pressure remained significantly sup­
pressed for 20 min after termination of the infusion. 
The renin inhibitor did not affect blood pressure dur­
ing ingestion of the high salt intake diet. 
The effects of the renin inhibitor on blood pressure 
were qualitatively similar when blood pressure was 
measured in the upright position. In the upright po­
sition, the renin inhibitor produced a drop in mean 
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F I G U R E 1. Effects of the renin inhibitor R-PEP-27 on mean 
arterial blood pressure measured in the supine position. The renin 
inhibitor R-PEP-27 was infused at 0.5, 1, 2, 4, 8, and 16 \iglkgl 
min for 10 min each beginning at t = 0, and ending at t = 60 
min. (*? < .05). 
arterial blood pressure from 98 ± 4 to 86 ± 4 (P < .01) 
during the low salt intake diet; there was no blood 
pressure drop during the high salt intake diet. 
Heart rate was unaffected by the renin-inhibitory 
peptide in the supine position (data not shown). Tilt­
ing into the upright position increased heart rate by 
8.4 ± 2.6 beats/min (P < .01) at the end of the renin-
inhibitor infusion during the low sodium intake diet. 
There were no significant changes in heart rate in 
response to renin inhibition during the high sodium 
intake diet (data not shown). 
Plasma Angiotensin II Concentration The renin-
inhibitory peptide produced a dose-dependent re­
duction in plasma angiotensin II concentration dur­
ing both diets (Figure 2). The numerical nadir in 
plasma angiotensin II concentration was reached dur­
ing infusion of the 4- and 8^g/min/kg body wt doses 
of R-PEP-27 during the high and low salt intake diets, 
respectively. Angiotensin II concentrations measured 
after infusion of the renin inhibitor at 2, 4, 8, and 16 
μg/kg/min did not differ significantly during the high 
salt intake diet. Plasma angiotensin II concentrations 
returned to pretreatment values in a time-dependent 
fashion after completion of the inhibitor infusion. 
The fall in blood pressure during R-PEP-27 infusion 
correlated linearly with the fall in plasma angiotensin 
II; the equation for this relationship was: y = 0.82x -
1.87, with y = change in mean arterial pressure (mm 
Hg) and χ = change in plasma angiotensin II concen­
tration (fmol/mL) (r = 0.9, Ρ < .01 for both the slope 
and intercept of this regression equation). 
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TABLE 1. EFFECTS OF RENIN INHIBITION ON 
BLOOD PRESSURE (SUPINE POSITION) 
Blood Pressure (mm Hg) 
Sodium-Deplete Diet Sodium-Replete Diet 
Time Systolic Diastolic Systolic Diastolic 
TABLE 1. continued 
Blood Pressure (mm Hg) 
Sodium-Deplete Diet Sodium-Replete Diet 
Time Systolic Diastolic Systolic Diastolic 
114 129 4 82 4 130 ± 6 73 ± 4 
116 126 ± 6 82 ± 4 128 ± 7 74 ± 4 
118 129 7 83 ± 4 129 ± 6 75 ± 4 
125 129 ± 5 82 5 129 ± 7 73 ± 4 
128 132 4 83 ± 4 129 ± 7 74 ± 4 
135 131 4 83 4 129 ± 6 77 ± 4 
138 132 ± 4 84 ± 3 127 ± 6 77 ± 4 
145 133 ± 3 84 4 127 ± 5 75 ± 4 
148 130 ± 4 87 ± 3 128 ± 8 77 ± 3 
155 130 4 81 ± 3 128 ± 7 73 ± 5 
158 128 3 80 ± 5 125 ± 6 77 ± 5 
165 132 ± 5 81 4 130 ± 8 75 ± 4 
168 132 ± 3 85 ± 3 127 ± 7 76 ± 3 
175 131 ± 2 85 ± 4 130 ± 6 76 ± 4 
178 130 ± 4 86 5 132 ± 7 79 ± 3 
Values recorded are the mean ± SEM (η = 6) of blood pressures recorded in the 
supine position. The value reported at time = 0 in Figure 1 represents the average 
of 12 recordings for each subject obtained during the 30 min immediately before 
starting the infusion of R-PEP-27. The renin inhibitor was infused at rates of 0.5 (t 
= OtolO min), lit = 10 to 20 min), 2 (t = 20 to 30 min), 4 (t = 30 to 40 min), 
8 (t = 40 to 50 min), and 16 (t = 50 to 60 min) \Lglminlkg. 
Plasma Aldosterone Concentration Plasma aldoste­
rone concentra t ion was depressed in a dose-
dependent fashion by the renin inhibitor during both 
diets (Figure 3). During salt restriction, the nadir in 
plasma aldosterone concentration was reached at the 
end of the infusion period. Plasma aldosterone con­
centration increased in a time-dependent fashion af­
ter termination of the infusion. During the high salt 
diet, little change from a lower baseline plasma aldo­
sterone concentration was observed. 
Adverse Effects In one patient the infusion of 
R-PEP-27 was associated with the development of 
second-degree Wenkebach-type atrioventricular 
block. Atrioventricular block occurred in this patient 
during both study periods during the infusion of 16 
0 20 40 60 80 100 120 140 160 180 
Time, minutes 
FIGURE 2. Effects of the renin inhibitor R-PEP-27 on plasma 
angiotensin II concentrations (*P < .05). 
- 3 0 126 ± 5 84 ± 4 129 ± 8 79 ± 6 
- 2 8 126 ± 6 85 ± 4 128 ± 7 79 ± 5 
- 2 6 134 ± 4 85 ± 3 128 ± 8 78 ± 5 
- 2 4 128 ± 6 84 ± 4 128 ± 8 80 ± 5 
- 2 2 126 ± 7 83 ± 4 129 ± 8 78 ± 4 
- 1 8 127 ± 6 84 ± 4 129 ± 9 78 ± 6 
- 1 6 130 ± 6 80 ± 5 127 ± 8 75 ± 6 
- 1 4 126 ± 6 81 ± 5 130 ± 9 73 ± 7 
- 1 2 127 ± 5 80 ± 5 128 ± 8 76 ± 5 
- 8 125 ± 5 81 ± 5 129 ± 8 75 ± 4 
- 6 130 ± 5 82 ± 5 132 ± 7 78 ± 5 
- 4 130 ± 5 82 ± 5 126 ± 7 74 ± 6 
- 2 128 ± 5 83 ± 5 126 ± 8 77 ± 4 
2 126 ± 4 80 ± 4 128 ± 8 75 ± 5 
4 128 ± 3 78 ± 4 125 ± 7 75 ± 5 
6 127 ± 3 79 ± 3 121 ± 6 75 ± 4 
8 122 ± 3 77 ± 3 122 ± 6 74 ± 5 
12 122 ± 3 79 ± 3 126 ± 6 73 ± 4 
14 123 ± 2 78 ± 5 126 ± 7 77 ± 5 
16 121 ± 4 77 ± 3 125 ± 6 75 ± 4 
18 120 ± 2 74 ± 4 126 ± 6 76 ± 5 
22 126 ± 4 75 ± 5 125 ± 4 76 ± 4 
24 122 ± 3 75 ± 5 126 ± 5 74 ± 4 
26 120 ± 2 76 ± 3 129 ± 7 75 ± 4 
28 122 ± 2 74 ± 2 124 ± 7 73 ± 4 
32 128 ± 6 75 ± 5 130 ± 7 73 ± 6 
34 125 ± 4 76 ± 5 122 ± 5 74 ± 4 
36 125 ± 6 76 ± 3 126 ± 7 73 ± 4 
38 118 ± 4 72 ± 4 124 ± 5 75 ± 4 
42 121 ± 6 75 ± 5 130 ± 8 74 ± 4 
44 122 ± 4 74 ± 4 127 ± 8 74 ± 6 
46 121 ± 3 74 ± 4 129 ± 9 72 ± 6 
48 122 ± 3 73 ± 5 129 ± 11 75 ± 6 
52 120 ± 5 72 ± 4 125 ± 8 74 ± 4 
54 123 ± 4 75 ± 4 128 ± 9 72 ± 4 
56 119 ± 3 70 ± 4 129 ± 9 74 ± 4 
58 121 ± 2 72 ± 3 128 ± 10 74 ± 4 
62 120 ± 4 74 ± 5 128 ± 9 74 ± 5 
64 118 ± 4 74 ± 5 126 ± 9 72 ± 5 
66 118 ± 4 75 ± 4 126 ± 9 74 ± 6 
68 120 ± 3 75 ± 4 124 ± 9 75 ± 5 
72 121 ± 5 70 ± 5 130 ± 7 76 ± 4 
74 123 ± 4 78 ± 5 131 ± 9 72 ± 4 
76 126 ± 4 77 ±5 131 ± 10 77 ± 6 
78 125 ± 2 77 ±5 131 ± 8 77 ± 3 
82 125 ± 2 79 ±3 127 ± 4 78 ± 4 
84 122 ± 3 79 ±2 129 ± 7 76 ± 5 
86 121 ± 3 77 ± 4 131 ± 7 75 ± 3 
88 125 ± 3 80 ± 4 129 ± 7 75 ± 4 
92 125 ± 5 82 ± 4 127 ± 6 78 ± 4 
94 130 ± 3 83 ± 4 127 ± 6 76 ± 4 
96 131 ± 5 85 ± 4 126 ± 7 76 ± 4 
98 128 ± 6 81 ± 4 125 ± 7 76 ± 5 
102 125 ± 6 82 ± 4 122 ± 7 75 ± 5 
104 129 ± 4 84 ± 2 129 ± 6 75 ± 4 
106 129 ± 4 83 ± 3 128 ± 7 75 ± 5 
108 129 ± 4 84 ± 3 125 ± 7 73 ± 4 
112 128 ± 4 83 ± 3 127 ± 7 74 ± 5 
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FIGURE 3. Effects of the renin inhibitor R-PEP-27 on plasma 
aldosterone concentrations (*P < .05). 
μg/min/kg body wt R-PEP-27. Normal atrioventricu­
lar conduction was restored within 10 min of discon­
tinuing the infusion. None of the other five subjects 
exhibited any electrocardiographic abnormalities. 
DISCUSSION 
The reduction in blood pressure after administration 
of the renin inhibitor R-PEP-27 was limited to subjects 
on a sodium-restricted diet; subjects receiving the 
diet containing 200 mEq of sodium daily had no he­
modynamic response. Of particular note is the strik­
ing parallelism of the fall in blood pressure (Figure 1) 
and changes in plasma angiotensin II concentrations 
(Figure 2). The temporal pattern of blood pressure fall 
and subsequent recovery after renin inhibition is vir­
tually identical to the changes seen in angiotensin II 
concentrations. On the low salt diet, plasma an­
giotensin II concentration and blood pressure were 
both lowest after infusion of the renin inhibitor for 60 
min; during the postinfusion period, angiotensin II 
levels were no longer suppressed 20 min after, and 
blood pressure was no longer suppressed 30 min af­
ter discontinuing the R-PEP-27 infusion. This rela­
tionship suggests that measurement of plasma an­
giotensin II concentrations is the most direct means of 
following the physiologic response to inhibition of 
the renin-angiotensin system. 
Similar striking parallelism was observed by com­
paring the angiotensin II profiles (Figure 2) with the 
aldosterone profiles (Figure 3) of our volunteers. As 
with blood pressure, more marked decreases in 
plasma aldosterone concentrations were found dur­
ing the low salt diet. Within an hour after stopping 
the renin-inhibitor infusion, aldosterone levels re­
turned to baseline, as did angiotensin II concentra­
tions and blood pressure. The increase in aldosterone 
levels after discontinuation of the infusion of the re­
nin inhibitor and after a rapid increase in plasma an­
giotensin II concentrations demonstrates a specific 
post-drug effect. 
The time-course of the renin inhibitory peptide's 
antihypertensive effect suggests that R-PEP-27 is a 
short-lived inhibitor of the renin-angiotensin system. 
Within 30 min after the renin inhibitor was discon­
tinued, blood pressure, angiotensin II concentration, 
and plasma aldosterone concentration returned to 
baseline or nearly baseline values. 
Our studies did not include a placebo observation 
period. Although the inclusion of such a period is 
often desirable, we believe our findings remain valid 
and are in no way diminished by the lack of a control 
group. The prolonged pretreatment observation pe­
riod established a stable baseline for subsequent com­
parison and the return of blood pressure after termi­
nation of the infusion to the precisely identical blood 
pressure as in the preinfusion period points to the 
stability of the patients' blood pressures throughout 
our experiment and the statistical validity of the 
comparisons. 
Varying responses have been observed in human 
subjects treated with renin-inhibitory peptides. Webb 
et a l 1 6 studied the hemodynamic response to the re­
nin inhibitor H-142 (Pro-His-Pro-Phe-His-Len-Val-Ile-
His-Lys) in subjects on a low salt diet who had been 
pretreated 72 h before the study with oral furose-
mide. Renin inhibition significantly reduced blood 
pressure in a dose-dependent fashion, and the 
plasma angiotensin concentration and renin activity 
fell. After discontinuation of the infusion, there was a 
rebound in plasma renin activity and angiotensin II 
concentrations above baseline, although blood pres­
sure did not exceed pretreatment values. Nussberger 
and colleagues 1 7 reported that in normal subjects on 
an unrestricted diet who were pretreated with furo-
semide (40 mg orally), the administration of CGP-
3 8 5 6 0 A (N- (2 (R) -benzy l -3 - t e r f -bu ty l - su l fony l -
proprionyl)His-Cha-Val-n-butylamide) did not affect 
blood pressure despite significant reductions in 
plasma renin activity and angiotensin II concentra­
tion. Similarly, Delabays and colleagues 1 8 reported 
only a slight reduction in blood pressure in normal 
subjects treated with enalkiren ([N-(3-amino-3-
methyl-l-oxobutyl)-4-methoxy-L-phenylalanyl]-N-
[(1S, 2R, 3S)-(l-cyclohexyl-methyl)-2,3-dihydroxy-5-
methylhexyl]-L-histidinamide) (Abbott 64662) despite 
significant reductions in plasma renin activity and 
plasma angiotensin II concentration. Total and active 
renin concentration in these subjects increased signif­
icantly during administration of the renin inhibitor, 1 8 
as in other studies of the effects of renin inhibition. 1 9 
Anderson et a l 2 0 have demonstrated that enalkiren 
significantly reduces the blood pressure, plasma re­
nin activity, and plasma aldosterone concentration in 
hypertensive subjects, but does not change urinary 
prostacyclin excretion. 
The collective experience to date with renin inhib­
itors shows that the response to renin inhibition de-
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pends on the dietary sodium intake, the species stud­
ied, and the chemical structure of the renin inhibitor 
used. Indeed, the mechanism of the hypotensive re­
sponse to a renin inhibitor can differ depending on 
the volume of distribution of the substance, its ability 
to penetrate into extravascular sites of renin activity, 
and its half-life. Experimental studies have shown 
that the renin inhibitor N-acetyl pepstatin suppresses 
vascular renin activity in isolated perfused rat mes­
enteric arteries, 2 1 whereas CGP-29287 has no effect 
on tissue renin activity measured in the brain, heart, 
aorta, and kidney of the marmoset. 2 2 
Whether R-PEP-27 penetrates tissue sites of renin 
activity cannot be determined with certainty from this 
study. Indeed, in view of evidence that angiotensin I 
plays a role in cardiac contraction and relaxation, 2 3" 2 6 
measurement of the systolic and diastolic properties 
of the myocardium of patients receiving ACE inhibi­
tors and/or renin inhibitors might demonstrate a dif­
ferent pattern of cardiac response to interruption of 
the renin-angiotensin cascade proximal to or distal to 
the generation of angiotensin I. 
No evidence currently shows that renin inhibitors 
offer a distinct hemodynamic advantage over an­
giotensin converting enzyme inhibitors in ambula­
tory hypertensive patients. Certainly, were a clini­
cally effective orally active renin inhibitor available 
for human u s e , 2 7 - 2 9 it might offer an advantage for 
patients who experience side effects from converting 
enzyme inhibition that are related to the non-renin-
mediated mechanism of action of these drugs; these 
side effects can include cough, angioedema, and skin 
rash. A specific, rapidly acting renin inhibitor could 
be of clinical utility for the treatment of patients with 
accelerated or malignant hypertension, or for those 
with acute congestive heart failure. Also, it could be 
valuable for the treatment of patients who are unable 
to take oral antihypertensive medications. Further 
studies with R-PEP-27 will be required to determine 
whether this peptide meets these requirements. 
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